Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Switching to Biosimilars for the Management of Psoriasis
An expert discusses how examining biosimilars in trials ensures safety, efficacy, and interchangeability, key for clinical adoption. The phase 3 study’s week 52 results confirmed consistent pharmacokinetics, efficacy, and safety. As confidence grows, biosimilars will expand treatment access for psoriasis patients.
EP: 1.Real-World Insights on Tildrakizumab
EP: 2.Tildrakizumab in Practice: Adherence and Clinical Takeaways
EP: 3.The VISIBLE Study: Understanding Comorbidities in Psoriasis Across All Skin Tones
EP: 4.Comparing Biologic Treatment Patterns: Tildrakizumab vs Ustekinumab
Now Viewing
EP: 5.Switching to Biosimilars for the Management of Psoriasis
Video content above is prompted by the following:
- Why is it so critical to examine biosimilars in clinical trials?
- Discuss the importance of interchangeability and whether it is implemented in your clinical practice.
- What were the study methods for this interchangeability study?
- What were the key results seen in terms of pharmacokinetics, efficacy, and safety profile?
- How do you see the use of biosimilars evolving in the future for patients with psoriasis?
Related Videos
Related Content
